A blended education program designed by Springer Healthcare IME, in collaboration with Dr Paul Cornes and Dr Michael Muenzberg, for all medical oncologists, specialist nurses and allied healthcare professionals (HCPs) working with patients for whom biosimilars may represent a treatment option.

Despite their promise, the uptake, and therefore benefits, of biosimilars in oncology has been slower than expected. A key barrier to their uptake is healthcare professional unfamiliarity with the  concept of biosimilarity. Despite an increase in medical education, there are several clinical and non-clinical factors that contribute to a lack of confidence among HCPs.

This program aims to provide you with a better understanding of the biosimilar development process and extrapolation of indications concept, and to help improve your confidence in prescribing biosimilars to your patients. Our goal is to focus on the key issues from your point of view in order to support you in resolving and overcoming these barriers.

This expert-led video module focuses on debating the best practice in patient communication when initiating or switching to a biosimilar treatment, with the aim to improve your confidence in explaining the important information to your patients, helping them to gain confidence in their use.

Scroll to Top

Paul Cornes

Dr Paul Cornes (BM BCH MA MRCP FRCR) has trained in Medicine at Oxford University and in Oncology at the Royal Marsden Hospital, London, UK before becoming a Consultant Oncologist in Bristol, UK.

He is part of the steering group for the European School of Oncology Working Party on the Access to Innovation in Cancer Treatment. He was on the faculty for the annual ECCO European CanCer Organisation meeting and ESMO-Barcelona – speaking on Innovation and Value-based medicine.

Paul was part of the team that developed and presented evidence to the Oncologic Drugs Advisory Committee of the FDA for the first successfully approved US biosimilar.  He is a faculty member for the Continuing Medical Education programme of the European Association of Hospital Pharmacists for 2016, 2017 & 2018 and a Core Lecturer for the European School of Oncology.

He is part of the British Medical Journal “Round Table” group on Biosimilars as well as a faculty member for the DIA Regulators Meeting on Biosimilars. He has been an adviser on medicines and biosimilars policy to several national health systems – both in the EU and beyond.

Disclosures

Paul Cornes has received travel costs to attend meetings and/or received speaker fees from Accord Healthcare; Astro; Biogen; the European Commission; the Global Academy of Health Sciences; GBM-Australia; Mylan, Napp; Pfizer/Hospira; Sandoz.

Ber Oomen

After completing his diploma, Ber Oomen trained as a general nurse before choosing to specialize in mental health nursing within a long-term, high-care clinical setting in 1980. In 2003, Ber joined the Dutch association for psychiatric nursing, as secretary, and was co-founder of the European Association for Psychiatric Nurses in Europe. He fulfilled the role of Secretary General within the organisation until 2009. In 2005, Ber took part in the first network meeting of the European Specialist Nurses Organisation (ESNO) and in 2008 accepted the position of secretary. He reformed the network into a European association based in Brussels, and was executive director for 12 years; he is currently senior advisor for ESNO. Since 2020, Ber has been director of the ESNO Foundation of Nurse Specialists Europe (FoNSE), which is responsible for shaping all ESNO projects.

As director of ESNO FoNSE, Ber is responsible for overall management of the association, being proactive in expanding the network of specialist nurses, advocating their role, and promoting recognition of their professional status at the European level. He is active in a variety of health programs: the Expert Group Health Workforce of DG Sante; the European Policy Platform; the EMA Health Professional Working Party; the OECD focus group on Skills Mismatches; the Joined Actions on Vaccination; and the Antimicrobial Resistance and Health Workforce. In 2018, Ber took on the role of project leader to create a nurses communication guide on biosimilars and was responsible for the content. He participated as an expert in the DG-Growth meeting on Biosimilars, took part in the biosimilars working group in the European Medicines Agency (EMA) and has been involved in various international events on biosimilars. In ESNO, he is project leader of the Switch Management Guideline for Nurses and, since 2021, has led a project to revise and update the first edition of the guide.

Disclosures

No disclosures to declare.

Alexandra Pereira

Alexandra Pereira completed her Nursing degree in July 1993. In August that year she began work as a nurse in a hospital specialising in Oncology, where since March 2004 she has performed roles in the outpatient department. During this time, she has administered standard outpatient treatments in accordance with her nursing skills, as well as providing overall patient care to administer these therapeutic regimens.

In April 2005, Alexandra assisted as a Study Nurse in a chemotherapy clinical trial, and has since participated in a number of other studies in this area. She graduated as a Medical-Surgical Nurse in July 2000 after completing a specialist course in Medical-Surgical Nursing.

Disclosures

No disclosures to declare.